Gonorrhea

Gonorrhea: Causes, Symptoms, Treatment, and Prevention

~Introduction

Gonorrhea is a sexually transmitted infection (STI) caused by the bacterium Neisseria gonorrhoeae. Commonly referred to as “the clap,” gonorrhea has been a recognized public health problem for centuries. It can infect the genital tract, rectum, and throat, and in some cases, even the eyes.

Gonorrhea is highly prevalent worldwide—particularly among sexually active adolescents and young adults—and is one of the most commonly reported bacterial STIs. While it can be cured with appropriate antibiotics, untreated gonorrhea can lead to serious complications, including infertility, pelvic inflammatory disease (PID), chronic pelvic pain, and increased vulnerability to HIV infection. Alarmingly, drug-resistant strains have emerged, making treatment increasingly challenging.

---

~Historical Background

The history of gonorrhea dates back to ancient times. The term comes from the Greek words gonos (seed) and rhoia (flow), reflecting an early belief that the pus-like discharge was semen. Records of the disease exist from ancient Chinese, Roman, and Egyptian texts.

During the late 19th century, Albert Neisser discovered the causative organism Neisseria gonorrhoeae, a gram-negative diplococcus. This paved the way for laboratory-based diagnosis and antibiotic treatment. Initially treated with sulfa drugs and later penicillin, gonorrhea was once easily curable. However, misuse and overuse of antibiotics have led to resistant strains, now classified by the WHO as a major public health threat.

---

~Causative Agent

Neisseria gonorrhoeae is:

• A gram-negative, kidney-shaped diplococcus.

• Non-motile and non-spore-forming.

• Capable of infecting mucous membranes lined with columnar epithelium, such as in the urethra, cervix, rectum, throat, and conjunctiva.

The bacterium attaches to epithelial cells using pili and surface proteins, evading the host immune response through antigenic variation.

---

~Transmission

Gonorrhea spreads through:

1. Sexual contact – vaginal, anal, or oral sex with an infected person.

2. Perinatal transmission – from mother to baby during childbirth, leading to neonatal conjunctivitis (ophthalmia neonatorum).

3. Indirect spread – extremely rare, as the bacterium does not survive well outside the human body.

Risk factors include:

• Multiple sexual partners.

• Unprotected sex.

• Previous or concurrent STIs.

• Young age (15–24 years).

---

~Incubation Period

The incubation period usually ranges from 2 to 7 days, but symptoms can appear later or not at all, especially in women.

---

~Signs and Symptoms

Gonorrhea can present differently in men, women, and extragenital sites. Importantly, many infected individuals are asymptomatic, which contributes to its spread.

In Men

• Urethritis with burning sensation during urination.

  
  
  

• White, yellow, or green penile discharge.

• Swollen or painful testicles (epididymitis in severe cases).

• Increased urinary frequency.

In Women

• Increased vaginal discharge.

• Pain during urination.

• Intermenstrual bleeding.

• Pelvic or abdominal pain (suggestive of PID).

• Pain during sexual intercourse.

Rectal Infection

• Anal itching.

• Discharge.

• Painful bowel movements.

• Bleeding.

Pharyngeal (Throat) Infection

• Often asymptomatic.

• Sore throat in some cases.

Neonatal Infection

• Eye redness and swelling.

• Thick pus discharge from eyes within days after birth.

---

~Complications

If untreated, gonorrhea can lead to serious and sometimes irreversible complications.

In Women

• Pelvic Inflammatory Disease (PID) – can cause chronic pain, infertility, and ectopic pregnancy.

• Increased risk of acquiring HIV.

In Men

• Epididymitis – inflammation of the tube carrying sperm, which may cause infertility.

• Prostatitis (rare).

In Both Sexes

• Disseminated Gonococcal Infection (DGI) – bacteria spread to the bloodstream, causing arthritis, skin lesions, and fever.

• Meningitis or endocarditis (rare but severe).

---

~Diagnosis

Accurate diagnosis is essential for effective treatment and prevention of spread.

1. Laboratory Tests

• Nucleic Acid Amplification Tests (NAATs) – the most sensitive and widely used, performed on urine samples or swabs from affected sites.

• Gram Stain – shows gram-negative diplococci inside white blood cells, useful in symptomatic men.

• Culture – allows antibiotic susceptibility testing, critical in resistant cases.

2. Screening

• Recommended for sexually active women under 25 years.

• Recommended for men who have intercourse with men (MSM), or individuals with new/multiple partners.

---

~Treatment

The rise of antibiotic resistance has significantly influenced treatment guidelines.

Current WHO and CDC Recommendations (as of 2024)

• First-line treatment:

  • Ceftriaxone 500 mg intramuscularly in a single dose

  • If chlamydial infection hasn’t been excluded, add Doxycycline 100 mg orally twice daily for 7 days.

Treatment for Pregnant Women

• Ceftriaxone is considered safe.

• Avoid doxycycline.

For Neonates

• Ceftriaxone 25–50 mg/kg IV or IM in a single dose.

Follow-Up

• Test-of-cure is recommended in certain cases, especially where resistance is suspected.

---

~Antibiotic Resistance: A Growing Threat

Gonorrhea is known as a “superbug” because N. gonorrhoeae has developed resistance to:

• Penicillin.

• Tetracyclines.

• Fluoroquinolones.

• Some macrolides.

Ceftriaxone remains effective in most regions, but reports of decreased susceptibility are increasing, prompting urgent calls for new drug development.

---

~Prevention

Preventing gonorrhea requires both individual and public health measures.

1. Safe Sexual Practices

• Use condoms consistently and correctly.

• Limit the number of sexual partners.

• Engage in mutual monogamy with an uninfected partner.

2. Regular Screening

• Especially important for sexually active individuals with multiple partners.

• Routine screening helps identify asymptomatic cases.

3. Partner Notification and Treatment

• All recent sexual partners (within 60 days) should be tested and treated.

• Abstain from sex until treatment is completed.

4. Perinatal Prevention

• Screening pregnant women for gonorrhea.

• Prompt treatment to prevent neonatal infection.

---

~Global Burden

According to the World Health Organization (WHO):

• Approximately 82 million new cases of gonorrhea occur annually worldwide.

• Highest rates are among people aged 15–24.

• The disease is more common in low- and middle-income countries, but rising rates are being reported in developed nations due to reduced condom use and changing sexual behavior.

---

~Public Health Challenges

• Stigma – discourages people from seeking testing.

• Asymptomatic cases – facilitate silent spread.

• Drug resistance – limits treatment options.

• Insufficient surveillance – underreporting masks the true scale.

---

~Research and Future Directions

• Development of a gonorrhea vaccine – early trials show some promise, particularly with cross-protection from certain meningococcal vaccines.

• New antibiotics – including zoliflodacin and gepotidacin in clinical trials.

• Enhanced diagnostic tools – rapid point-of-care tests for resistance detection.

---

~Case Example: The UK Resistant Strain (2018)

In 2018, the UK reported a case of gonorrhea resistant to both ceftriaxone and azithromycin—two of the most important drugs used for treatment. The patient had acquired the infection abroad, highlighting the need for global coordination in antimicrobial stewardship.

---

~Living with Gonorrhea

While gonorrhea can be cured, living with the infection—especially if untreated—can be life-altering due to complications like infertility or chronic pain. Education, regular screening, and honest communication with partners are essential for sexual health.

---

~Conclusion

Gonorrhea is a preventable and curable infection, but the rise of drug-resistant strains poses a serious threat to global health. The key to control lies in:

• Prevention through safer sexual practices.

• Early detection and prompt treatment.

• Partner notification and treatment.

• Ongoing surveillance and research.

In a world where antibiotic resistance is making treatment more complex, awareness and responsibility are crucial. Gonorrhea’s history reminds us that medical progress can be undone without vigilance, making it essential to act decisively to protect both individual and public health.